Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Richard A. Paulson M.B.A. | President, CEO & Director | 1.43M | -- | 1967 |
| Ms. Sohanya Cheng M.B.A. | Executive VP, Chief Commercial Officer & Head of Business Development | 742.95k | -- | 1983 |
| Mr. Stuart Poulton | Executive VP & Chief Development Officer | 682.48k | -- | 1973 |
| Dr. Reshma Rangwala M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Research | 777.32k | -- | 1979 |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board & Independent Director | 150k | -- | 1961 |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1.4M | -- | 1970 |
| Ms. Lori A. Macomber CPA | EVP, CFO & Treasurer | -- | -- | 1972 |
| Ms. Kristin Abate | VP, Chief Accounting Officer & Assistant Treasurer | -- | -- | -- |
| Mr. Brendan Twohig Strong | SVP of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Michael J. Mano J.D. | Senior VP, General Counsel & Secretary | 625.08k | -- | 1978 |
Karyopharm Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 279
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Corporate Governance
Upcoming Events
May 6, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Karyopharm Therapeutics Inc. Earnings Date